Company Overview and News

 
Trump Makes American Cannabis Great Again, say Eight Public Companies

2018-04-17 globenewswire
LAS VEGAS, April 17, 2018 (GLOBE NEWSWIRE) -- Player’s Network, Inc. (OTCQB:PNTV), a publicly traded diversified holding company operating in marijuana, announced it has joined with eight publicly traded marijuana companies to applaud recent pronouncements from President Trump that he will support a legislative solution to protect states’ ability to regulate marijuana within their own borders.
Upvote Downvote

 
CLS Holdings USA, Inc. Announces Plan to Monetize Its U.S. Patent Allowance and Patent Filings in Canada and the 38 Countries covered by the European Patent Organization For Its Proprietary Conversion and Extraction Process

2018-04-10 marketwired
LAS VEGAS, NV--(Marketwired - April 10, 2018) - CLS Holdings USA, Inc. (OTCQB: CLSH) "CLS," a development stage diversified cannabis company operating as Cannabis Life Sciences, is pleased to announce its strategy to monetize its proprietary conversion and extraction process. CLS has received a patent allowance in the United States with respect to its proprietary conversion and extraction process and has made additional patent filings in Canada and the 38 countries that are part of the European Patent Organization.
Upvote Downvote

 
CLS Holdings USA, Inc. Acquisition Target Oasis Cannabis Records Highest Wholesale Sales Month in March

2018-04-03 marketwired
City Trees Wholesale Sales Will Exceed $370,000 in March 2018 with 68% Growth Over February 2018
Upvote Downvote

 
CLS Holdings USA, Inc. Acquisition Target Oasis Cannabis Records Highest Single Day Sales

2018-03-15 marketwired
LAS VEGAS, NV--(Marketwired - March 15, 2018) - CLS Holdings USA, Inc. (OTCQB: CLSH) "CLS," a development stage diversified cannabis company operating as Cannabis Life Sciences, today announced that its acquisition target, Oasis Cannabis, recorded its largest sales date on record since July 1, 2017, when Nevada first began allowing retail sales to adults over 21 years of age.
Upvote Downvote

 
CLS Holdings USA's Acquisition Target Oasis Cannabis Finalizes Plans to Expand Capacity

2018-03-13 marketwired
LAS VEGAS, NV--(Marketwired - March 13, 2018) - CLSHoldings USA, Inc. (OTCQB: CLSH) "CLS," a development stage diversified cannabis company operating as Cannabis LifeSciences, today announced that its planned acquisition target, Oasis Cannabis, has finalized construction plans for the initial expansion of its City Trees wholesale cultivation and production facility.
Upvote Downvote

 
CLSH / CLS Holdings USA, Inc. 8-K (Current Report)

2018-02-26 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2018 CLS HOLDINGS USA, INC. (Exact name of registrant as specified in its charter) Nevada 333-174705 45-1352286 (State or other jurisdiction of incorporation) (Commission File Number) (I.
Upvote Downvote

 
CLSH / CLS Holdings USA, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-20 fintel.io
CLS Holdings USA, Inc. (OTC:CLSH) has 3 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 29,865,297 shares. Largest shareholders include Koretsky Frank, Binder Jeffrey I, and Vjra Corp.
Upvote Downvote

 
CLSH / CLS Holdings USA, Inc. / Koretsky Frank - SC 13D/A (Activist Investment)

2018-02-20 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE  13D   Under the Securities Exchange Act of 1934 (Amendment No. 1)* CLS Holdings USA, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 12565J100  (CUSIP Number) Jeffrey I. Binder c/o CLS Holdings USA, Inc. 1435 Yarmouth Street Boulder, Colorado  80304 (888) 438-9132 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) January 5, 2018 (Date of Event Which Re
Upvote Downvote

 
CLSH / CLS Holdings USA, Inc. / Koretsky Frank - SC 13D/A (Activist Investment)

2018-02-20 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE  13D   Under the Securities Exchange Act of 1934 (Amendment No. 1)* CLS Holdings USA, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 12565J100  (CUSIP Number) Jeffrey I. Binder c/o CLS Holdings USA, Inc. 1435 Yarmouth Street Boulder, Colorado  80304 (888) 438-9132 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) January 5, 2018 (Date of Event Which Re
Upvote Downvote

 
CLSH / CLS Holdings USA, Inc. / BINDER JEFFREY I - SC 13D/A (Activist Investment)

2018-02-17 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549     SCHEDULE 13D     Under the Securities Exchange Act of 1934   (Amendment No. 1)*   CLS Holdings USA, Inc.   (Name of Issuer) Common Stock (Title of Class of Securities) 12565J100   (CUSIP Number) Jeffrey I. Binder c/o CLS Holdings USA, Inc. 1435 Yarmouth Street Boulder, Colorado  80304 (888) 438-9132   (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) January 5, 2018 (Date of Ev
Upvote Downvote

 
CLSH / CLS Holdings USA, Inc. 8-K (Current Report)

2018-02-17 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2018 CLS HOLDINGS USA, INC. (Exact name of registrant as specified in its charter) Nevada   333-174705   45-1352286 (State or other jurisdiction of incorporation)   (Commission  File Number)   (I.
Upvote Downvote

 
CLSH / CLS Holdings USA, Inc. / BINDER JEFFREY I - SC 13D/A (Activist Investment)

2018-02-17 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549     SCHEDULE 13D     Under the Securities Exchange Act of 1934   (Amendment No. 1)*   CLS Holdings USA, Inc.   (Name of Issuer) Common Stock (Title of Class of Securities) 12565J100   (CUSIP Number) Jeffrey I. Binder c/o CLS Holdings USA, Inc. 1435 Yarmouth Street Boulder, Colorado  80304 (888) 438-9132   (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) January 5, 2018 (Date of Ev
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...